Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Pharmaceutical combination comprising a CIP2A silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired P53 function

Pharmaceutical combination comprising a CIP2A silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired P53 function

US Patent 9968630 · Granted May 15, 2018

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CIP2A variant and uses thereof2023
Combination Therapy III2019
Method of selecting individualized brain cancer therapy2018
Combination therapy2016
Pharmaceutical combination comprising a CIP2A silencing agent for use in the tre2016
Pharmaceutical combination comprising a CIP2A silencing agent for use in the tre2016
Use of a growth-stimulating protein2015
Use of a growth-stimulating protein2013